epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Emgality (galcanezumab-gnlm)
    galcanezumab
  • remove Farxiga
    dapagliflozin
  • remove modafinil
    generic
  • remove Steglatro
    ertugliflozin

multicheck MultiCheck Results - 2 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Farxiga (dapagliflozin) + Steglatro (ertugliflozin)

Avoid/Use Alternative


dapagliflozin + ertugliflozin

avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis), other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

Smiley face Smiley face Emgality (galcanezumab-gnlm) (galcanezumab) + modafinil (generic)

Monitor/Modify Tx


galcanezumab + modafinil

monitor BP: combo may incr. risk of HTN (additive effects)

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information